BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 35095911)

  • 1. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors.
    Qin VM; Haynes NM; D'Souza C; Neeson PJ; Zhu JJ
    Front Immunol; 2021; 12():813832. PubMed ID: 35095911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation CAR T cells to overcome current drawbacks.
    Lundh S; Maji S; Melenhorst JJ
    Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
    Knochelmann HM; Smith AS; Dwyer CJ; Wyatt MM; Mehrotra S; Paulos CM
    Front Immunol; 2018; 9():1740. PubMed ID: 30140266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.
    Bansal R; Reshef R
    Blood Rev; 2021 Jan; 45():100695. PubMed ID: 32402724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
    Feucht J; Abou-El-Enein M
    Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
    [No Abstract]   [Full Text] [Related]  

  • 11. CAR-T therapy: Prospects in targeting cancer stem cells.
    Cui X; Liu R; Duan L; Cao D; Zhang Q; Zhang A
    J Cell Mol Med; 2021 Nov; 25(21):9891-9904. PubMed ID: 34585512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient combination of radiotherapy and CAR-T - A systematic review.
    Szlasa W; Sztuder A; Kaczmar-Dybko A; Maciejczyk A; Dybko J
    Biomed Pharmacother; 2024 May; 174():116532. PubMed ID: 38574625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?
    Huan T; Li H; Tang B
    Front Immunol; 2022; 13():1033512. PubMed ID: 36466874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
    Yu YD; Kim TJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
    Johnson A; Townsend M; O'Neill K
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.